HU227123B1 - Pharmaceutical combination comprising amlodipine and lisinopril and it's use for the treatment of certain cardiovascular disorders - Google Patents
Pharmaceutical combination comprising amlodipine and lisinopril and it's use for the treatment of certain cardiovascular disorders Download PDFInfo
- Publication number
- HU227123B1 HU227123B1 HU0202416A HU020246A HU227123B1 HU 227123 B1 HU227123 B1 HU 227123B1 HU 0202416 A HU0202416 A HU 0202416A HU 020246 A HU020246 A HU 020246A HU 227123 B1 HU227123 B1 HU 227123B1
- Authority
- HU
- Hungary
- Prior art keywords
- amlodipine
- lysinopril
- treatment
- lisinopril
- hypertension
- Prior art date
Links
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 title claims abstract description 30
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 title claims abstract description 28
- 229960000528 amlodipine Drugs 0.000 title claims abstract description 22
- 238000011282 treatment Methods 0.000 title claims abstract description 18
- 108010007859 Lisinopril Proteins 0.000 title claims description 31
- 229960002394 lisinopril Drugs 0.000 title claims description 16
- 208000024172 Cardiovascular disease Diseases 0.000 title claims description 3
- 206010020772 Hypertension Diseases 0.000 claims abstract description 25
- 239000000203 mixture Substances 0.000 claims description 11
- 239000003826 tablet Substances 0.000 claims description 10
- 230000035488 systolic blood pressure Effects 0.000 claims description 7
- ZPBWCRDSRKPIDG-UHFFFAOYSA-N amlodipine benzenesulfonate Chemical compound OS(=O)(=O)C1=CC=CC=C1.CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl ZPBWCRDSRKPIDG-UHFFFAOYSA-N 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 229960004005 amlodipine besylate Drugs 0.000 claims description 5
- 238000009472 formulation Methods 0.000 claims description 5
- -1 lysinopril dihydrate Chemical class 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 230000004043 responsiveness Effects 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 239000007909 solid dosage form Substances 0.000 claims description 3
- 239000008188 pellet Substances 0.000 claims description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 claims 1
- 230000009286 beneficial effect Effects 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 201000010099 disease Diseases 0.000 abstract description 2
- 230000004044 response Effects 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 16
- 230000036772 blood pressure Effects 0.000 description 11
- 239000003814 drug Substances 0.000 description 10
- 229940079593 drug Drugs 0.000 description 9
- 230000009467 reduction Effects 0.000 description 6
- 230000001631 hypertensive effect Effects 0.000 description 5
- 238000009097 single-agent therapy Methods 0.000 description 5
- 206010019280 Heart failures Diseases 0.000 description 4
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 4
- 238000011260 co-administration Methods 0.000 description 4
- 230000035487 diastolic blood pressure Effects 0.000 description 4
- 230000003205 diastolic effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000002411 adverse Effects 0.000 description 3
- 238000011284 combination treatment Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 2
- 239000002876 beta blocker Substances 0.000 description 2
- 229940097320 beta blocking agent Drugs 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 229940030606 diuretics Drugs 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010014418 Electrolyte imbalance Diseases 0.000 description 1
- 208000007530 Essential hypertension Diseases 0.000 description 1
- 206010029412 Nightmare Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229960004530 benazepril Drugs 0.000 description 1
- 238000009530 blood pressure measurement Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000002565 electrocardiography Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000010503 organ complication Effects 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000010972 statistical evaluation Methods 0.000 description 1
- 210000002820 sympathetic nervous system Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU0202416A HUP0202416A3 (en) | 2002-07-24 | 2002-07-24 | Novel pharmaceutical combination and it's use for the treatment of certain cardiovascular disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HU227123B1 true HU227123B1 (en) | 2010-07-28 |
Family
ID=89980644
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0202416A HU227123B1 (en) | 2002-07-24 | 2002-07-24 | Pharmaceutical combination comprising amlodipine and lisinopril and it's use for the treatment of certain cardiovascular disorders |
| HU0202416A HUP0202416A3 (en) | 2002-07-24 | 2002-07-24 | Novel pharmaceutical combination and it's use for the treatment of certain cardiovascular disorders |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0202416A HUP0202416A3 (en) | 2002-07-24 | 2002-07-24 | Novel pharmaceutical combination and it's use for the treatment of certain cardiovascular disorders |
Country Status (1)
| Country | Link |
|---|---|
| HU (2) | HU227123B1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP0401170A2 (en) | 2004-06-10 | 2006-09-28 | Richter Gedeon Vegyeszet | Pharmaceutical composition comprising amlodipine besilate and lisinopril dihydrate and process for |
-
2002
- 2002-07-24 HU HU0202416A patent/HU227123B1/hu unknown
- 2002-07-24 HU HU0202416A patent/HUP0202416A3/hu unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0202416A2 (hu) | 2004-04-28 |
| HUP0202416A3 (en) | 2006-01-30 |
| HU0202416D0 (enExample) | 2002-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1212081B2 (en) | Use of ramipril in the prevention of congestive heart failure | |
| US12102623B2 (en) | Compositions for the treatment of hypertension | |
| CA2500662A1 (en) | Dosage escalation and divided daily dose of anti-depressants to treat neurological disorders | |
| Bayley et al. | Nifedipine in the treatment of hypertension: report of a double‐blind controlled trial. | |
| CN116603066A (zh) | 用于治疗高血压的组合物 | |
| Janini et al. | Enalapril in Raynaud's phenomenon | |
| JP4728955B2 (ja) | 口腔アフタの治療用の組成物を製造するためのヒアルロン酸の使用 | |
| Schulte et al. | Relation of regression of left ventricular hypertrophy to changes in ambulatory blood pressure after long-term therapy with perindopril versus nifedipine | |
| JP2002535367A5 (enExample) | ||
| HU227123B1 (en) | Pharmaceutical combination comprising amlodipine and lisinopril and it's use for the treatment of certain cardiovascular disorders | |
| Myers | Twenty-four-hour blood pressure control: a brief review of aspects of target-organ protection | |
| Fogari et al. | Effect of low-dose manidipine on ambulatory blood pressure in very elderly hypertensives | |
| Kinnunen et al. | Placebo‐controlled double‐blind trial of pirprofen and an ergotamine tartrate compound in migraine attacks | |
| Gradman et al. | Comparison of sustained-release formulations of nicardipine and verapamil for mild to moderate systemic hypertension | |
| Dobrowolski et al. | Use of antihypertensive combination therapy during the COVID-19 pandemic-a cross-sectional, nation-wide study 2019-2021 | |
| Krämer et al. | Nimodipine in Acute IschemicStroke: Results of the Nimodipine German-Austrian Stroke Trial | |
| Carter et al. | Once‐Daily Propranolol for Hypertension: A Comparison of Regular‐Release, Long‐Acting, and Generic Formulations | |
| Widmann et al. | Safety and antihypertensive efficacy of carvedilol and atenolol alone and in combination with hydrochlorothiazide | |
| JPH0645548B2 (ja) | 高血圧症予防・治療剤 | |
| Aliot et al. | Safety of a controlled-release flecainide acetate formulation in the prevention of paroxysmal atrial fibrillation in outpatients | |
| Smith et al. | A comparative study of atenolol, nifedipine and their combination in the treatment of hypertension | |
| RU2828226C2 (ru) | Композиции для лечения гипертензии | |
| Licata et al. | Multicenter, double-blind clinical trial with different doses of pinacidil in patients with mild-to-moderate essential hypertension | |
| HUP0300403A2 (hu) | Vérnyomáscsökkentő hatóanyagok és alkalmazásuk gyógyszerkészítmények előállítására | |
| Fukiyama et al. | Efficacy and safety of ramipril (HOE 498) in the treatment of hypertension: dose finding study |